Clinical significance of Ki-67 proliferation index in disease progression and prognosis of patients with resected colorectal carcinoma

British Journal of Surgery

Volumn 92, Issue 8, 2005, Pages 1002-1007

  Valera, V ^a,c   Yokoyama, N ^a   Walter, B ^a   Okamoto, H ^a   Suda, T ^b   Hatakeyama, K ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Graduate School of Life Dentistry at Niigata   (Japan)

^c First Department of Internal Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; KI 67 ANTIGEN; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RECTUM RESECTION; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 23844499121     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4858     Document Type: Article

References (23)

1. van Diest PJ, Brugal G, Baak JP. Proliferation markers in tumours: interpretation and clinical value. J Clin Pathol 1998; 51: 716-724.
2. Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfeld AG. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988; 154: 223-235.
3. Jansen RL, Hupperets PS, Arends JW, Joosten-Achjanie SR, Volovics A, Schouten HC et al. MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 1998; 78: 460-465.
4. Muller W, Schneiders A, Meier S, Hommel G, Gabbert HE. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996; 74: 759-765.
5. Ramires M, David L, Leitao D, Seixas M, Sansonetty F, Sobrinho-Simoes M. Ki67 labelling index in gastric carcinomas. An immunohistochemical study using double staining for the evaluation of the proliferative activity of diffuse-type carcinomas. J Pathol 1997; 182: 62-67.
6. Hoos A, Stojadinovic A, Mastorides S, Urist MJ, Polsky D, Di Como CJ et al. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 2001; 92: 869-874.
7. Pujol JL, Simony J, Jolimoy G, Jaffuel D, Demoly P, Quantin X et al. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers. Br J Cancer 1996; 74: 964-970.
8. McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999; 79: 191-203.
9. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-994.
10. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002; 40: 2-11.
11. Leader M, Patel J, Makin C, Henry K. An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology 1986; 10: 1315-1324.
12. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP et al. (eds). American Joint Committee on Cancer Staging Manual (5th edn). Lippincott-Raven: Philadelphia, 1997; 224-226.
13. Ohtani H. Lymphocytes and macrophages as possible prognostic factors in human colorectal cancer. Acta Histochem Cytochem 2000; 33: 63-66.
14. Porschen R, Kriegel A, Langen C, Classen S, Hilse M, Lohe B et al. Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki-67 immunostaining. Int J Cancer 1991; 47: 686-691.
15. Kubota Y, Petras RE, Easley KA, Bauer TW, Tubbs RR, Fazio VW. Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 1992; 70: 2602-2609.
16. Diebold J, Dopfer K, Lai M, Lohrs U. Comparison of different monoclonal antibodies for the immunohistochemical assessment of cell proliferation in routine colorectal biopsy specimens. Scand J Gastroenterol 1994; 29: 47-53.
17. Kyzer S, Gordon PH. Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67. Dis Colon Rectum 1997; 40: 322-325.
18. Kikuchi Y, Dinjens WN, Bosman FT. Proliferation and apoptosis in proliferative lesions of the colon and rectum. Virchows Arch 1997; 431: 111-117.
19. Chen Y-T, Henk MJ, Carney K-J, Wong WD, Rothenberger DA, Zheng T et al. Prognostic significance of tumor markers in colorectal cancer patients: DNA index, S-phase fraction, p53 expression, and Ki-67 index. J Gastrointest Surg 1997; 1: 266-273.
20. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999; 84: 225-233.
21. Shepherd NA, Richman PI, England J. Ki-67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations. J Pathol 1988; 155: 213-219.
22. Suzuki H, Matsumoto K, Terabe M. Ki-67 antibody labeling index in colorectal carcinoma. J Clin Gastroenterol 1992; 15: 317-320.
23. Saleh HA, Jackson H, Khatib G, Banerjee M. Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia. Pathol Oncol Res 1999; 5: 273-279.